FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/New Clinical Trial Compares Bariatric Surgery to Semaglutide and Tirzepatide
연구 도서관으로 돌아가기

New Clinical Trial Compares Bariatric Surgery to Semaglutide and Tirzepatide

May 25, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

New Clinical Trial Compares Bariatric Surgery to Semaglutide and Tirzepatide

A recent study published on ClinicalTrials.gov aims to shed light on how the latest anti-obesity medications stack up against traditional surgical treatments. The Phase 4 trial, sponsored by Ali Aminian, is set to compare bariatric surgery with two leading peptide therapies: semaglutide and tirzepatide.

This study comes at a time when the landscape of obesity treatment is rapidly changing due to advancements in peptide therapy. Researchers are eager to understand how these newer medications measure up against surgical interventions that have been the gold standard for severe cases of obesity.

Background

Obesity, a condition affecting millions worldwide, often requires aggressive intervention beyond diet and exercise alone. Traditionally, bariatric surgery has been the go-to option for those with extreme weight issues and related health complications. However, recent years have seen the introduction of powerful peptide-based medications like semaglutide and tirzepatide that promise significant weight loss without the risks associated with surgery.

These medications work by mimicking hormones involved in digestion to increase feelings of fullness and regulate blood sugar levels. They are particularly appealing for patients who might not be surgical candidates due to age, medical history, or personal preference. The goal is to determine if these new treatments can offer comparable benefits to bariatric surgery but with fewer risks.

Key Details

The trial involves a comparison between three interventions: bariatric surgery, semaglutide, and tirzepatide. Researchers are tracking weight loss percentages, changes in body composition, and improvements in obesity-related medical conditions such as type 2 diabetes, hypertension, and cardiovascular disease. The study is currently active but not recruiting participants.

Semaglutide and tirzepatide both belong to the class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which have been shown in previous studies to induce substantial weight loss over extended periods. These medications are administered through subcutaneous injections once a week or daily, depending on the specific regimen prescribed.

Bariatric surgery, on the other hand, involves altering the digestive system to reduce calorie intake and absorption. Common procedures include gastric bypass and sleeve gastrectomy. While these surgeries yield high weight loss rates, they come with significant risks including infection, blood clots, and nutritional deficiencies.

Key Takeaways

  • Semaglutide and Tirzepatide Show Promising Results: Early studies have demonstrated that these peptide therapies can lead to an average of 15-22% weight reduction over a year.
  • Bariatric Surgery Remains a Gold Standard for Severe Cases: For patients with severe obesity (BMI > 40) or those with comorbidities like type 2 diabetes, bariatric surgery continues to be an effective option despite its risks.
  • Comparative Efficacy of Non-Surgical and Surgical Interventions: The trial aims to clarify whether semaglutide and tirzepatide can provide comparable outcomes to bariatric surgery for weight loss and management of obesity-related diseases.
  • Advancements in Peptide Therapy Highlight New Treatment Avenues: As research into peptide-based treatments expands, the field offers new hope for patients seeking non-invasive alternatives to traditional surgical methods.

What This Means

For the peptide community, this study represents a significant step forward in understanding how newer medications can compete with established surgical options. If semaglutide and tirzepatide prove equally effective as bariatric surgery, it could shift treatment paradigms towards more accessible non-surgical interventions for obesity.

Moreover, this research underscores the growing importance of peptide therapy in treating complex health conditions like obesity. As these treatments continue to evolve, they may offer a safer alternative for many patients who might otherwise be unable or unwilling to undergo major surgical procedures.

---

Source: ClinicalTrials.gov — Published 2026-05-18

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.